3β,21-dihydroxy-17α,20-epoxy-5-pregnene | 1094211-42-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β,21-dihydroxy-17α,20-epoxy-5-pregnene
• 英文别名: 3beta,21-Dihydroxy-17alpha,20-epoxy-5-pregnene；(3S,8R,9S,10R,13S,14S,17R)-3'-(hydroxymethyl)-10,13-dimethylspiro[1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,2'-oxirane]-3-ol
• CAS: 1094211-42-3
• 化学式: C₂₁H₃₂O₃
• 分子量: 332.483
• InChiKey: FMOHTQBFGJULLE-HNFJNZPISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  53
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Pregna-5,17(20)-dien-3β,21-diol 在 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 以75%的产率得到3β,21-dihydroxy-17α,20-epoxy-5-pregnene
  参考文献：
  名称：

  NEUROSTEROID COMPOUNDS

  摘要：

  本发明涉及具有抗凋亡、神经保护和神经生成特性的新型神经类固醇衍生物，其作用于神经系统，以及制备这些衍生物的方法以及它们在治疗和/或预防或改善与神经元凋亡或神经元损伤相关的神经退行性疾病或与凋亡相关或由凋亡导致的疾病，包括但不限于阿尔茨海默病、帕金森病、亨廷顿病、多发性硬化症和肌萎缩侧索硬化症（ALS）、视网膜变性和脱离、由遗传异常引起的周围神经病变、糖尿病、小儿麻痹症、疱疹、艾滋病和化疗、脑外伤、缺血和中风。活性化合物由式（I）表示：其中R1、R2、R3、R4、R5、R6、R7、A、B、X、Y和Z在本发明描述中有定义。本发明还包括包含式（I）中的一个或多个化合物的组合物。

  公开号：

  US20100234335A1

文献信息

• [EN] LIPID PRODRUGS OF NEUROSTEROIDS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES
  申请人：PURETECH LYT INC

  公开号：WO2021159021A1

  公开（公告）日：2021-08-12

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统导向的脂质前药、其药物组合物、制备此类前药和组合物的方法，以及提高包含在脂质前药中的治疗剂的生物利用度或其他特性的方法。本发明还提供了治疗如本文所述的疾病、紊乱或状况的方法，包括向有需要的患者施用所述的脂质前药或其药物组合物。
• USE OF STEROID COMPOUNDS FOR INFLAMMATORY AND AUTOIMMUNE DISORDERS
  申请人：Bionature E.A. Ltd.

  公开号：EP2475369A1

  公开（公告）日：2012-07-18
• LIPID PRODRUGS OF NEUROSTEROIDS
  申请人：PureTech LYT, Inc.

  公开号：EP4100017A1

  公开（公告）日：2022-12-14
• USE OF STEROID COMPOUNDS
  申请人：Panoutsakopoulou Vasiliki

  公开号：US20120225852A1

  公开（公告）日：2012-09-06

  This invention pertains to the use of steroid compounds including spirosteroid analogues in treating, preventing or ameliorating the symptoms of inflammatory conditions. The steroid compounds are useful for treating a range of inflammatory conditions, including, but not limited to asthma, lung inflammation, retinal inflammatory conditions, autoimmune diseases such as rheumatoid arthritis, diabetes type I, systemic lupus erythematosus, ulcerative colitis and inflammatory bowel diseases and myopathies, as well as multiple sclerosis. The active compounds are represented by Formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , A, B, X, Y and Z are defined in the description of the invention.
• COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION
  申请人：Pharmatrophix, Inc.

  公开号：US20220031641A1

  公开（公告）日：2022-02-03

  Provided are compositions and methods comprising agonists. Also disclosed are agonist compounds, pharmaceutical compositions of agonists, and methods of using the same.